136 related articles for article (PubMed ID: 20171968)
21. Human purified CD8+ T cells: Ex vivo expansion model to generate a maximum yield of functional cytotoxic cells.
Al-Shanti N; Aldahoudi Z
Immunol Invest; 2007; 36(1):85-104. PubMed ID: 17190652
[TBL] [Abstract][Full Text] [Related]
22. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
[TBL] [Abstract][Full Text] [Related]
23. A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples.
Jackson HM; Dimopoulos N; Chen Q; Luke T; Yee Tai T; Maraskovsky E; Old LJ; Davis ID; Cebon J; Chen W
J Immunol Methods; 2004 Aug; 291(1-2):51-62. PubMed ID: 15345304
[TBL] [Abstract][Full Text] [Related]
24. Antigen-nonspecific activation of CD8+ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancer.
Ramanathan S; Gagnon J; Ilangumaran S
Arch Immunol Ther Exp (Warsz); 2008; 56(5):311-23. PubMed ID: 18836862
[TBL] [Abstract][Full Text] [Related]
25. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
[TBL] [Abstract][Full Text] [Related]
26. Expansion of natural killer cell receptor (CD94/NKG2A)-expressing cytolytic CD8 T cells and CD4+CD25+ regulatory T cells from the same cord blood unit.
Tanaka J; Sugita J; Kato N; Toubai T; Ibata M; Shono Y; Ota S; Kondo T; Kobayashi T; Kobayashi M; Asaka M; Imamura M
Exp Hematol; 2007 Oct; 35(10):1562-6. PubMed ID: 17681668
[TBL] [Abstract][Full Text] [Related]
27. Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells.
Nishimura E; Sakihama T; Setoguchi R; Tanaka K; Sakaguchi S
Int Immunol; 2004 Aug; 16(8):1189-201. PubMed ID: 15237110
[TBL] [Abstract][Full Text] [Related]
28. Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes.
Lu J; Giuntoli RL; Omiya R; Kobayashi H; Kennedy R; Celis E
Clin Cancer Res; 2002 Dec; 8(12):3877-84. PubMed ID: 12473603
[TBL] [Abstract][Full Text] [Related]
29. In-vitro generation and characterisation of murine CD4+CD25+ regulatory T cells with indirect allospecificity.
Tsang J; Jiang S; Tanriver Y; Leung E; Lombardi G; Lechler RI
Int Immunopharmacol; 2006 Dec; 6(13-14):1883-8. PubMed ID: 17161341
[TBL] [Abstract][Full Text] [Related]
30. Comparative analysis of dendritic cells and anti-CD3/CD28 expanded regulatory T cells for application in transplantation.
Zeng M; Guinet E; Nouri-Shirazi M
Transpl Immunol; 2009 Dec; 22(1-2):82-92. PubMed ID: 19635560
[TBL] [Abstract][Full Text] [Related]
31. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.
Tam YK; Martinson JA; Doligosa K; Klingemann HG
Cytotherapy; 2003; 5(3):259-72. PubMed ID: 12850795
[TBL] [Abstract][Full Text] [Related]
32. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.
Bae J; Martinson JA; Klingemann HG
Clin Cancer Res; 2005 Feb; 11(4):1629-38. PubMed ID: 15746068
[TBL] [Abstract][Full Text] [Related]
33. Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells.
Numbenjapon T; Serrano LM; Chang WC; Forman SJ; Jensen MC; Cooper LJ
Exp Hematol; 2007 Jul; 35(7):1083-90. PubMed ID: 17588477
[TBL] [Abstract][Full Text] [Related]
34. Telomerase-specific T-cells kill pancreatic tumor cells in vitro and in vivo.
Schmidt J; Ryschich E; Sievers E; Schmidt-Wolf IG; Büchler MW; Märten A
Cancer; 2006 Feb; 106(4):759-64. PubMed ID: 16369992
[TBL] [Abstract][Full Text] [Related]
35. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells.
Mackinnon S; Thomson K; Verfuerth S; Peggs K; Lowdell M
Blood Cells Mol Dis; 2008; 40(1):63-7. PubMed ID: 17869548
[TBL] [Abstract][Full Text] [Related]
36. Non-MHC-dependent redirected T cells against tumor cells.
Almåsbak H; Lundby M; Rasmussen AM
Methods Mol Biol; 2010; 629():453-93. PubMed ID: 20387166
[TBL] [Abstract][Full Text] [Related]
37. Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion.
Brimnes MK; Gang AO; Donia M; Thor Straten P; Svane IM; Hadrup SR
Cancer Immunol Immunother; 2012 Aug; 61(8):1221-31. PubMed ID: 22237888
[TBL] [Abstract][Full Text] [Related]
38. Adoptive therapy using antigen-specific T-cell clones.
Yee C
Cancer J; 2010; 16(4):367-73. PubMed ID: 20693849
[TBL] [Abstract][Full Text] [Related]
39. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.
Berger C; Jensen MC; Lansdorp PM; Gough M; Elliott C; Riddell SR
J Clin Invest; 2008 Jan; 118(1):294-305. PubMed ID: 18060041
[TBL] [Abstract][Full Text] [Related]
40. Adoptive Transfer of CD8+ T Cells Generated from Induced Pluripotent Stem Cells Triggers Regressions of Large Tumors Along with Immunological Memory.
Saito H; Okita K; Chang AE; Ito F
Cancer Res; 2016 Jun; 76(12):3473-83. PubMed ID: 27197199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
